ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan ARIAD Pharmaceuticals, Inc. today announced the initiation of a multi-center Phase 1/2 medical trial in Japan of ponatinib, the business’s investigational BCR-ABL inhibitor www.sildenafil-100mg.org . The trial has been conducted in Japanese individuals with chronic myeloid leukemia who’ve failed treatment with dasatinib or nilotinib or with Philadelphia-chromosome positive acute lymphoblastic leukemia who’ve failed prior tyrosine kinase inhibitors.
ASA has long been a supporter of efforts to lessen the misuse, abuse and diversion of prescription drugs, and we applaud the President for increasing awareness of this ailment and making safe use of prescription opioids a priority for his administration. In 2013, ASA caused the White House Office of National Drug Control Policy to develop an informational cards that delivers easy-to-understand lifesaving ways to help family and friends save someone suspected of an opioid overdose. As part of this effort, the informational card created by ASA will be distributed by the Fraternal Order of Police to its 330,000 members..